CURIS INC
No SEC Form 4 filings for $CRIS in the last 30 days.
See all $CRIS insider activity →Curis, Inc. (CRIS) priced a public offering with certain healthcare-focused institutional investors for 3.733 million shares or pre-funded warrants plus warrants. Combined price is $1.50 per share, with expected gross proceeds of about $5.6 million, closing around Aug. 14, 2026. Warrants exercise at $1.75, pre-funded warrants at $0.01. CRIS focuses on Emavusertib (CA-4948).
Curis (NASDAQ:CRIS) reported progress in clinical programs for its oral IRAK4 and FLT3 inhibitor targeting blood cancers. HC Wainwright said TakeAim CLL enrollment is ahead of plan, with year-end guidance raised to 5-10 patients, and reiterated a Buy rating while lifting its price target from $17 to $43. The note also updated emavusertib valuation assumptions and shifted PCNSL launch to 2029 and AML/MDS to 2032.
Curis Inc. (NASDAQ:CRIS) reported updated clinical results for emavusertib and expanded trial timeline guidance. In its TakeAim Primary CNS Lymphoma study, overall response was 100% (5/5) in BTK-naive evaluable patients and 86% (6/7) overall. BTK-experienced response was 26% (10/39). In TakeAim CLL, Curis added sites and raised its year-end data target to 5-10 patients in Dec 2026.
Over the past 7 days, alphai's AI scored 1 news story mentioning CRIS (CURIS INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent CRIS coverage spans financial news, corporate actions and technology.
The priced equity and warrant issuance is dilutive and can pressure near-term valuation, while providing cash runway for Emavusertib trials.
Raised CLL enrollment/guidance and shifted launch timelines increase perceived probability-weighted value for emavusertib, supporting bullish sentiment into upcoming PCNSL/CLL data.
The trial efficacy update and accelerated CLL enrollment guidance are likely to support near-term sentiment and raise probability of further clinical milestones.
Positive updated clinical efficacy data plus higher CLL enrollment guidance likely supports near-term sentiment and probability of regulatory progress.
The after-hours move is directly tied to the effective date of a reverse split and the start of split-adjusted trading.
alphai scores every news story that mentions CRIS with an AI model for sentiment and relevance, and aggregates insider trades from CURIS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Curis, Inc. (CRIS) priced a public offering with certain healthcare-focused institutional investors for 3.733 million shares or pre-funded warrants plus warrants. Combined price is $1.50 per share, with expected gross proceeds of about $5.6 million, closing around Aug. 14, 2026. Warrants exercise at $1.75, pre-funded warrants at $0.01. CRIS focuses on Emavusertib (CA-4948).
2 min readCuris (NASDAQ:CRIS) reported progress in clinical programs for its oral IRAK4 and FLT3 inhibitor targeting blood cancers. HC Wainwright said TakeAim CLL enrollment is ahead of plan, with year-end guidance raised to 5-10 patients, and reiterated a Buy rating while lifting its price target from $17 to $43. The note also updated emavusertib valuation assumptions and shifted PCNSL launch to 2029 and AML/MDS to 2032.
5 min readCuris Inc. (NASDAQ:CRIS) reported updated clinical results for emavusertib and expanded trial timeline guidance. In its TakeAim Primary CNS Lymphoma study, overall response was 100% (5/5) in BTK-naive evaluable patients and 86% (6/7) overall. BTK-experienced response was 26% (10/39). In TakeAim CLL, Curis added sites and raised its year-end data target to 5-10 patients in Dec 2026.
4 min readCuris, Inc. (NASDAQ:CRIS) shares rose about 11% after the company reported updated emavusertib clinical data in primary CNS lymphoma and raised enrollment guidance for its chronic lymphocytic leukemia study. In PCNSL, it cited an 86% overall response rate in BTK inhibitor-naïve and 26% in BTKi-experienced patients as of July 1, 2026. For CLL, it guided year-end enrollment to 5-10 patients.
4 min readCuris Inc. (NASDAQ:CRIS) shares rose 8.51% to $0.46 after hours Wednesday after the company confirmed its previously approved reverse stock split will take effect Thursday at 5:00 p.m. ET, with split-adjusted trading starting Jul. 6. Shareholders approved a 1-for-5 to 1-for-25 split to help regain Nasdaq’s $1 bid compliance.
3 min readCuris (NASDAQ: CRIS) said 11 clinical sites are open for patient enrollment in its Phase 2 TakeAim CLL study of emavusertib plus zanubrutinib. The company reaffirmed dosing of the first five patients by end-July 2026 and expects data in December 2026. Stockholders approved a reverse stock split (1-for-5 to 1-for-25) to help regain Nasdaq bid-price compliance.
4 min readCURIS INC (CRIS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cris-20260625 0001108205 false 0001108205 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date
3 min readCuris Inc. (CRIS) reported a significant Q1 2026 miss, with GAAP diluted EPS of -$1.25 against an estimated -$0.40, and $0 revenue compared to an estimated $1.49 million. The revenue shortfall was due to the prior sale of Erivedge royalties, while the widened net loss was primarily attributed to a non-cash warrant liability revaluation from a January 2026 PIPE financing. Despite this, the company's cash balance improved, and R&D expenses decreased, indicating disciplined cost management, though its business model remains capital-intensive.
3 min readCuris (NASDAQ: CRIS) reported a significantly wider net loss of $24.2 million in Q1 2026, up from $10.6 million in Q1 2025, with revenue dropping to zero after the sale of its Erivedge royalty stream. Despite a January 2026 PIPE financing that boosted cash to $15.0 million, the company indicated current funds are insufficient for the next 12 months and that future operations depend on additional financing, including potential Series B warrant exercises. Curis is advancing emavusertib in multiple cancer trials and expects key clinical data readouts by the end of 2026 and early 2027.
3 min readCuris (CRIS) delivered earnings and revenue surprises of +20.97% and +8.58%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min read
